Prevention of pneumococcal disease from 24 serotypes not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL”In the company’s words, NCT07943585 on ClinicalTrials.gov
- Tested for
- Pneumococcal Infectious Disease
- Main trialPhase 3
- “A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.”In the company’s words, NCT07943585 on ClinicalTrials.gov
Other drugs for Pneumococcal Infectious Disease
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- PG4Pfizer · Phase 3
- Pneumococcal conjugate vaccinePfizer · Phase 3
- PrevnarPfizer · Phase 3
Coming up1
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07943585
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Oct 2027 | A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026